◀ Back to HIF1A

EGLN1 — HIF1A

Pathways - manually collected, often from reviews:

• KEGG Pathways in cancer: EGLN1/EGLN2/EGLN3 → EPAS1/HIF1A (protein-protein, missing interaction)
• KEGG Renal cell carcinoma: EGLN1/EGLN2/EGLN3 → EPAS1/HIF1A (protein-protein, activation)
• Reactome Reaction: HIF1A → EGLN1 (reaction) Jaakkola et al., Science 2001, Ivan et al., Science 2001, Bruick et al., Science 2001, Ivan et al., Proc Natl Acad Sci U S A 2002*, Metzen et al., J Cell Sci 2003, Hirsilä et al., J Biol Chem 2003*, Berra et al., EMBO J 2003*, Appelhoff et al., J Biol Chem 2004*, Tuckerman et al., FEBS Lett 2004*, Fedulova et al., Protein Expr Purif 2007*, Rantanen et al., Mol Biol Cell 2008*, Tian et al., J Biol Chem 2011*
• WikiPathways Photodynamic therapy-induced HIF-1 survival signaling: EGLN1 → HIF1A (inhibition)

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Bind_translation Interaction: HIF1A — EGLN1 (affinity chromatography technology) Baek et al., Mol Cell 2005*
• IRef Bind_translation Interaction: HIF1A — EGLN1 (coimmunoprecipitation) Baek et al., Mol Cell 2005*
• IRef Bind_translation Interaction: HIF1A — EGLN1 (experimental interaction detection) Isaacs et al., Cancer Cell 2005*
• IRef Biogrid Interaction: HIF1A — EGLN1 (physical association, affinity chromatography technology) Choi et al., J Biol Chem 2010*
• IRef Biogrid Interaction: HIF1A — EGLN1 (association, x-ray crystallography) Chowdhury et al., Structure 2009*
• IRef Biogrid Interaction: HIF1A — EGLN1 (direct interaction, pull down) Percy et al., Proc Natl Acad Sci U S A 2006*
• IRef Biogrid Interaction: HIF1A — EGLN1 (direct interaction, pull down) Baek et al., Mol Cell 2005*
• IRef Biogrid Interaction: HIF1A — EGLN1 (direct interaction, pull down) Yoo et al., Oncogene 2008*
• MIPS CORUM HIF1A-OS9-EGLN1 complex: HIF1A-OS9-EGLN1 complex complex (EGLN1-HIF1A-OS9) Baek et al., Mol Cell 2005*
• IRef Dip Interaction: HIF1A — EGLN1 (direct interaction, x-ray crystallography) Chowdhury et al., Structure 2009*
• IRef Hprd Interaction: Complex of EGLN1-HIF1A-MTA1-EGLN1-MTA1-HIF1A-EGLN1-HIF1A-MTA1 (in vivo) Yoo et al., EMBO J 2006
• IRef Hprd Interaction: HIF1A — EGLN1 (in vivo) Tuckerman et al., FEBS Lett 2004*, Baek et al., Mol Cell 2005*, Yoo et al., EMBO J 2006
• IRef Hprd Interaction: HIF1A — EGLN1 (in vitro) Tuckerman et al., FEBS Lett 2004*, Baek et al., Mol Cell 2005*, Yoo et al., EMBO J 2006
• IRef Innatedb Interaction: HIF1A — EGLN1 (unknown, -) Barth et al., Mol Cell Biol 2007*
• IRef Innatedb Interaction: HIF1A — EGLN1 (unknown, -) Scholz et al., Proc Natl Acad Sci U S A 2013
• IRef Intact Interaction: Complex of 16 proteins (association, anti tag coimmunoprecipitation) Baek et al., Mol Cell 2005*
• IRef Intact Interaction: Complex of HIF1A-EGLN1-VHL (physical association, two hybrid) Bex et al., Nucleic Acids Res 2007
• IRef Intact Interaction: HIF1A — EGLN1 (hydroxylation reaction, experimental interaction detection) Tuckerman et al., FEBS Lett 2004*
• IRef Intact Interaction: HIF1A — EGLN1 (physical association, anti tag coimmunoprecipitation) Yoo et al., EMBO J 2006
• IRef Intact Interaction: HIF1A — EGLN1 (physical association, anti bait coimmunoprecipitation) Yoo et al., EMBO J 2006
• IRef Intact Interaction: HIF1A — EGLN1 (enzymatic reaction, enzymatic study)

Text-mined interactions from Literome

Marxsen et al., Biochem J 2004 (Adenocarcinoma, Clear Cell...) : In the human osteosarcoma cell line, U2OS, selective suppression of HIF-1alpha expression by RNA interference resulted in a complete loss of hypoxic induction of PHD2 and PHD3
Choi et al., Mol Pharmacol 2005 : Overexpression of PHD2 lacking the MYND domain caused a greater reduction in the stability and function of HIF-1alpha than did overexpression of wild-type PHD2, indicating that the MYND domain also inhibits the catalytic activity of PHD2 in vivo
To et al., J Biol Chem 2005 : In this study, we demonstrated that apart from promoting HIF-1alpha proteolysis in normoxia, EGLN1 specifically represses HIF-1alpha transcriptional activity in hypoxia ... Ectopic expression of EGLN1 inhibited HIF-1alpha transcriptional activity without altering its protein levels in a von Hippel-Lindau-deficient cell line, indicating a discrete activity of EGLN1 in transcriptional repression ... Conversely, silencing of EGLN1 expression augmented HIF-1alpha transcriptional activity and its target gene expression in hypoxia
Jokilehto et al., Clin Cancer Res 2006 (Carcinoma, Squamous Cell...) : Furthermore, they imply that even the elevated PHD2 levels are not sufficient to down-regulate HIF-1alpha in some tumors
Ietta et al., Biol Reprod 2006 (Anoxia) : Inhibition of EGLN activity increased HIF1A stability in villous explants and stimulated transforming growth factor beta 3 ( TGFB3 ) expression consistent with promoter analyses showing that HIF1A transactivates TGFB3
Takeda et al., Hypertension 2007 (Anoxia) : Indeed, overexpression of a mutant PHD2 lacking hydroxylase activity also greatly diminished EC response to hypoxia induced increase in proliferation, in spite of the fact that hypoxia induced HIF-1alpha accumulation was not affected by mutant PHD2
Villar et al., Biochem J 2007 : In the present study we showed that whereas EGLN1 and EGLN2 acted upon any of these ODDs to regulate HIF1alpha protein levels and activity in vivo, EGLN3 only acted on the CODD
Wang et al., Hypertension 2010 : The present study tested the hypothesis that PHD2 responds to high salt and mediates high-salt induced increase in HIF-1alpha levels in the renal medulla